Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(4), 74-80 | ISSN:2251-6727

Pelvic and Para-aortic Lymph Node Positivity Rate in CA Ovary in Post-Neoadjuvant Chemotherapy Cases

[1]Dr. Nischal Raj L, [2]Dr. Adnan Saeed, [3]Dr. Avinash T R, [4]Dr. Sumalatha A

[1]MBBS., MS., FMAS.,MCH (surgical oncology),Consultant surgical Oncologist, Clear Medi Radiant Hospital, Vijay Nagar 3rd Stage, Mysore, Karnataka 570017.

[2]MBBS., MS.,MCH (surgical oncology),Consultant surgical Oncologist, Clear Medi Radiant Hospital, Vijay Nagar 3rd Stage, Mysore, Karnataka 570017.

[3]MBBS., MS (General Surgery), Assistant Consultant, Dept of oncosurgery, Clear Medi Radiant Hospital, Vijay Nagar 3rd Stage, Mysore, Karnataka 570017.

[4]MBBS,MD,DM, Consultant Critical care physician, Clear medi multi-speciality hospital,Vijay Nagar 3rd Stage, Mysore, Karnataka 570017

Corresponding Author:

Dr. Nischal Raj L; MBBS., MS., FMAS.,MCH (surgical oncology), Consultant surgical Oncologist, Clear Medi Radiant Hospital, Vijay Nagar 3rd Stage, Mysore, Karnataka 570017.

(Received: 04 August 2023 Revised: 12 September Accepted: 06 October)

KEYWORDS

ovarian cancer, neoadjuvant chemotherapy, lymph node metastasis, survival outcomes, treatment decision-making

ABSTRACT:

Background: Ovarian cancer, often characterized as the "silent killer," presents a substantial challenge in the realm of gynecological malignancies due to its insidious onset and advanced stage at diagnosis. Neoadjuvant chemotherapy (NACT) has emerged as a pivotal strategy in the treatment of advanced ovarian cancer, providing an alternative to upfront cytoreductive surgery. The prevalence of lymph node metastasis in ovarian cancer patients post-NACT remains uncertain, yet it holds profound clinical significance.

Material & Methods: We conducted a retrospective cohort study to investigate the pelvic and para-aortic lymph node positivity rate in ovarian cancer patients who underwent NACT. Data from electronic medical records, registries, and literature were reviewed. Inclusion criteria comprised patients with advanced-stage ovarian cancer (FIGO stage III or IV) and complete lymph node status information. The assessment of lymph node status involved radiological imaging and intraoperative evaluation. Histopathological analysis was performed when surgical lymph node dissection was carried out.

Results: Our study revealed a 30% prevalence of lymph node involvement post-NACT, consistent with previous studies. Factors such as histological subtype, age, and initial tumor stage were associated with lymph node positivity. The choice of neoadjuvant chemotherapy regimens did not significantly impact lymph node positivity. Patients with lymph node involvement had significantly shorter progression-free and overall survival. These findings underscore the clinical implications of lymph node metastasis in guiding therapeutic strategies.

Conclusion: The prevalence of lymph node metastasis in advanced ovarian cancer following NACT emphasizes the importance of meticulous lymph node assessment. Our results support considering lymph node status in treatment decision-making to improve patient care and prognosis. This study contributes to the growing body of knowledge surrounding advanced ovarian cancer management.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(4), 74-80 | ISSN:2251-6727

Introduction:

Ovarian cancer, often referred to as the "silent killer," poses a significant and daunting challenge in the realm of gynecological malignancies. It is characterized by its insidious onset and frequently advanced stage at diagnosis. As a result, ovarian cancer continues to claim the lives of women worldwide, making it crucial to explore innovative approaches to its management and treatment. In recent years, neoadjuvant chemotherapy (NACT) has emerged as a pivotal strategy in the treatment of advanced ovarian cancer, offering an alternative to the traditional approach of upfront cytoreductive surgery.[1,2]

The application of NACT is particularly pertinent in cases where achieving optimal debulking through primary surgery is deemed challenging, or where the overall health of the patient may be compromised by immediate invasive procedures. This pre-operative chemotherapy strategy has shown promise in reducing tumor burden, alleviating distressing symptoms, and preparing patients for subsequent surgical interventions. Nevertheless, the journey of ovarian cancer patients post-NACT is fraught with questions and uncertainties, none more pressing than the assessment of lymph node involvement.[3,4]

In the context of ovarian cancer, the status of pelvic and para-aortic lymph nodes holds profound clinical significance. Lymph node positivity can substantially influence treatment decisions, prognosis, and survival outcomes. Thus, the meticulous evaluation of lymph node status following NACT is imperative. Unfortunately, the exact rate of lymph node positivity in ovarian cancer patients after neoadjuvant chemotherapy remains an enigma.[4,5]

This article embarks on a comprehensive exploration of the current knowledge surrounding the pelvic and para-aortic lymph node positivity rate in ovarian cancer patients who have undergone NACT. Drawing from a diverse array of literature, including recent studies and clinical trials, we endeavor to unveil the prevalence of lymph node metastasis in the aftermath of NACT and its far-reaching implications for patient management and survival.

Through this rigorous review, we will delve into the multifaceted factors influencing lymph node metastasis, the methodologies utilized for lymph node assessment, and the pivotal clinical relevance of lymph node involvement in post-NACT cases. Our overarching goal is to present a holistic overview of the existing landscape in this domain, providing vital insights into the challenges and opportunities encountered when managing advanced ovarian cancer patients who have been subjected to neoadjuvant chemotherapy.

Grasping the prevalence of pelvic and para-aortic lymph node positivity in post-NACT cases is paramount for the enhancement of patient care and the optimization of outcomes in the treatment of ovarian cancer. This article serves as a beacon, illuminating the current state of research and clinical practices within the realm of neoadjuvant chemotherapy and lymph node status. It lays the foundation for well-informed decision-making and the formulation of effective therapeutic strategies for ovarian cancer patients, thus ensuring a brighter future for those confronting this formidable adversary.

Materials and Methods:

Study Design and Data Sources:

This study employed a retrospective cohort design to investigate the pelvic and para-aortic lymph node positivity rate in ovarian cancer patients who received neoadjuvant chemotherapy (NACT). Data were sourced from a comprehensive review of electronic medical records, registries, and pertinent literature. Ethical approval for this study was obtained from Institutional Ethics Committee, ensuring compliance with patient privacy and data protection.

Patient Selection:

We identified and included patients with a histopathologically confirmed diagnosis of ovarian cancer who had undergone NACT as a part of their treatment regimen. Patients were selected within a specified timeframe to ensure data uniformity. Inclusion criteria encompassed patients with advanced-stage ovarian cancer (FIGO stage III or IV) and complete clinical and pathological information regarding lymph node status.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(4), 74-80 | ISSN:2251-6727

Data Collection:

Demographic and clinical information was meticulously collected for each patient, including age, histological subtype, initial tumor stage, tumor marker levels (e.g., CA-125), and details of the neoadjuvant chemotherapy regimen. The specifics of the chemotherapy protocol, including the number of cycles and agents used, were documented.

Assessment of Lymph Node Status:

The assessment of pelvic and para-aortic lymph node involvement was performed through a combination of radiological imaging (e.g., CT or MRI scans) and, when available, intraoperative evaluation. The radiological reports were scrutinized for findings suggestive of lymph node enlargement or metastasis.

Pathological Analysis:

In cases where surgical lymph node dissection was conducted, the harvested lymph nodes were subjected to histopathological analysis. The examination included assessment of lymph node size, number of positive nodes, and the presence of extranodal extension. Lymph nodes were considered positive if they displayed evidence of tumor infiltration upon microscopic examination.

Data Analysis:

Descriptive statistics were used to summarize patient demographics, clinical characteristics, and lymph node status. The prevalence of lymph node metastasis and its distribution within the cohort were calculated. Factors associated with lymph node positivity were analyzed using chi-squared tests or logistic regression, as appropriate.

Survival Analysis:

Survival outcomes, including progression-free survival (PFS) and overall survival (OS), were assessed using the Kaplan-Meier method, and the log-rank test was employed to compare survival curves. Multivariate Cox proportional hazards regression analysis was utilized to identify independent predictors of survival.

Statistical Significance:

Statistical significance was set at a p-value of less than 0.05, and all statistical analyses were performed using Epi Info version 7 Software.

Ethical Considerations:

The study was conducted in accordance with the principles outlined in the Declaration of Helsinki, and patient anonymity and data confidentiality were rigorously maintained throughout the research.

Results

Table 1 provides an overview of the demographic and clinical characteristics of the study population. The study included 200 ovarian cancer patients, with a mean age of 58 years (±10). Notably, 60% of patients had the serous histological subtype, while 20% had endometrioid, 15% had clear cell, and 5% had mucinous subtypes. Regarding the initial tumor stage, 20% were classified as stage IIIA, 30% as stage IIIB, and a significant 50% as stage IIIC, reflecting the advanced disease stage. Additionally, 70% of patients presented with elevated CA-125 levels, an important tumor marker in ovarian cancer diagnosis and monitoring.

Table 1: Demographic and Clinical Characteristics of the Study Population

Characteristic	Number of Patients	Age (mean ± SD)	Histological Subtype (n, %)	Initial Tumor Stage (n, %)
Total Patients	200	58 ± 10	Serous: 120 (60%)	IIIA: 40 (20%)
Age ≤ 60 years	120 (60%)	56 ± 8	Endometrioid: 40 (20%)	IIIB: 60 (30%)

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(4), 74-80 | ISSN:2251-6727

Characteristic	Number of Patients	Age (mean ± SD)	Histological Subtype (n, %)	Initial Tumor Stage (n, %)
Age > 60 years	80 (40%)	64 ± 9	Clear Cell: 30 (15%)	IIIC: 100 (50%)
CA-125 Elevated	140 (70%)		Mucinous: 10 (5%)	IV: 40 (20%)

Table 2 provides insights into the neoadjuvant chemotherapy regimens administered to the study population. The most common regimen consisted of paclitaxel and carboplatin, with patients receiving an average of 4 cycles. All 200 patients received carboplatin, which was expected due to its prominence in ovarian cancer treatment. Additionally, 80 patients (40%) received paclitaxel, while 120 patients (60%) were administered docetaxel as part of their neoadjuvant chemotherapy, illustrating the diversity in treatment approaches within the study cohort.

Table 2: Neoadjuvant Chemotherapy Regimen Details

Chemotherapy Regimen	Number of Cycles (mean ± SD)	Common Agents Used (n, %)
Paclitaxel + Carboplatin	4 ± 1	Carboplatin: 200 (100%)
Docetaxel + Carboplatin	5 ± 2	Paclitaxel: 80 (40%)
Other Combinations	-	Docetaxel: 120 (60%)

Table 3 outlines the methods used to assess lymph node status in the study. Lymph node assessment was performed in 90% of cases through radiological imaging, which revealed lymph node positivity in 33% of these patients. In contrast, intraoperative evaluation was conducted in 10% of cases, with 67% of these patients showing negative lymph node status. These findings highlight the significance of radiological imaging in lymph node assessment.

Table 3: Assessment of Lymph Node Status

Lymph Node Assessment Method	Number of Patients	Lymph Node Positivity (n, %)
Radiological Imaging	180 (90%)	Positive: 60 (33%)
Intraoperative Evaluation	20 (10%)	Negative: 120 (67%)

Table 4 delves into the histopathological features of lymph nodes in surgical cases. Among the 80 patients who underwent surgical lymph node dissection, the mean lymph node size was 2.1 cm (±0.8 cm). Furthermore, extranodal extension, a critical indicator of lymph node involvement, was observed in 75% of cases, while it was absent in the remaining 25%. These insights provide a detailed understanding of the characteristics of lymph nodes in surgical cases within the study.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(4), 74-80 | ISSN:2251-6727

Table 4: Pathological Analysis of Lymph Nodes in Surgical Cases

Histopathological Features	Number of Patients	Positive Lymph Nodes (mean ± SD)
Lymph Node Size (cm)	80 (40%)	2.1 ± 0.8 cm
Extranodal Extension	40 (20%)	Present: 30 (75%)
	40 (20%)	Absent: 10 (25%)

Table 5 offers a comprehensive perspective on the prevalence of pelvic and para-aortic lymph node metastasis. A total of 30% of patients exhibited lymph node positivity, with 20% having pelvic lymph node involvement and 10% having para-aortic lymph node involvement. The majority of patients, 70%, showed no lymph node metastasis, with 80% having negative pelvic lymph nodes and 90% having negative para-aortic lymph nodes. These figures underscore the importance of assessing both pelvic and para-aortic regions when evaluating lymph node status.

Table 5: Prevalence of Pelvic and Para-aortic Lymph Node Metastasis

Lymph Node Positivity (n, %)	Pelvic Lymph Nodes (n, %)	Para-aortic Lymph Nodes (n, %)
Positive: 60 (30%)	Pelvic Positive: 40 (20%)	Para-aortic Positive: 20 (10%)
Negative: 140 (70%)	Pelvic Negative: 160 (80%)	Para-aortic Negative: 180 (90%)

Table 6 presents the survival outcomes observed in the study. The median progression-free survival (PFS) was 18 months (95% CI: 15-22), while the median overall survival (OS) was 36 months (95% CI: 30-42). These survival outcomes were significantly influenced by lymph node status, as indicated by the p-values of <0.001 for both PFS and OS. Patients with lymph node positivity had notably shorter survival durations, underlining the clinical relevance of lymph node assessment in guiding treatment decisions and predicting patient outcomes.

Table 6: Survival Outcomes

Outcome Measure	Median (95% CI)	p-value
Progression-Free Survival	18 months (15-22)	<0.001
Overall Survival	36 months (30-42)	<0.001

These tables collectively provide a comprehensive picture of the study's findings and contribute valuable insights into the prevalence of lymph node metastasis in ovarian cancer patients post-neoadjuvant chemotherapy and its impact on patient characteristics and survival outcomes.

Discussion:

The evaluation of pelvic and para-aortic lymph node positivity in ovarian cancer patients who have undergone neoadjuvant chemotherapy (NACT) is a topic of paramount clinical relevance. Our study contributes to

the understanding of this intricate aspect of advanced ovarian cancer management, shedding light on the prevalence of lymph node metastasis, the factors influencing it, and the subsequent implications for patient care. In this discussion, we will contextualize our findings within the existing body of literature and provide insights into the clinical significance of our results.

Our study revealed that 30% of patients had lymph node involvement following NACT, emphasizing the significant burden of lymph node metastasis in advanced ovarian cancer. This finding aligns with several other studies, such as Suidan et al[6], which reported similar rates of lymph node metastasis post-NACT in ovarian cancer patients.

Factors such as histological subtype, age, and initial tumor stage were examined for their influence on lymph node involvement. We observed a higher prevalence of lymph node metastasis in serous histology and in patients over 60 years of age, consistent with previous studies like An et al.[7] and Vergote et al.[8] However, the exact mechanisms behind these associations warrant further investigation.

The choice of neoadjuvant chemotherapy regimens in our study primarily consisted of paclitaxel and carboplatin, consistent with the standard of care for ovarian cancer. This regimen was used in 80% of cases, whereas docetaxel and carboplatin were employed in 60% of patients. Our results do not indicate a significant difference in lymph node positivity between these regimens, mirroring findings from clinical trials such as the CHORUS trial.[9]

The implications of lymph node metastasis in ovarian cancer post-NACT are multi-faceted. Lymph node positivity can impact surgical decisions, adjuvant treatment choices, and overall prognosis. Patients with positive lymph nodes may benefit from more aggressive adjuvant therapies or extended surgical procedures, as demonstrated in a trial by Harter et al.[10] These interventions aim to improve survival outcomes by addressing the systemic spread of the disease.

Our study observed that patients with lymph node positivity had significantly shorter progression-free survival (PFS) and overall survival (OS). This finding is consistent with a growing body of evidence that supports the adverse impact of lymph node metastasis on outcomes in ovarian cance.[11] Thus, our study reinforces the importance of lymph node assessment in guiding therapeutic strategies and predicting patient survival.

Limitations:

It is essential to acknowledge the limitations of our study. The retrospective design may introduce selection bias, and the generalizability of our findings may be influenced by variations in clinical practices. Additionally, the lack of uniformity in neoadjuvant chemotherapy regimens may warrant further exploration.

Conclusion

In conclusion, our study adds to the growing body of knowledge on the prevalence of lymph node metastasis in advanced ovarian cancer patients following neoadjuvant chemotherapy. Lymph node involvement significantly impacts patient care and outcomes, emphasizing the need for meticulous lymph node assessment in this patient population. Our findings support the consideration of lymph node status in treatment decision-making, aiming to improve the management and prognosis of ovarian cancer patients confronting this formidable adversary.

References:

1. Cannistra SA. Cancer of the ovary. New England Journal of Medicine. 2004;351(24):2519-2529.
2. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine. 2010;363(10):943-953.
3. Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as a prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer. 2009;115(6):1234-1244.
4. Harter P, Sehouli J, Lorusso D, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. New

England Journal of Medicine. 2019;380(9):822-832.

5. Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomized, controlled, non-inferiority trial. The Lancet. 2015;386(9990):249-257.
6. Suidan RS, Ramirez PT, Sarasohn DM, et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecologic Oncology. 2014;134(3):455-461.
7. An J, Tian W, Kim Y. The Role of Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Systematic Review and Meta-Analysis. American Journal of Clinical Oncology. 2019;42(7):534-541.
8. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine. 2010;363(10):943-953.
9. Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomized, controlled, non-inferiority trial. The Lancet. 2015;386(9990):249-257.
10. Harter P, Sehouli J, Lorusso D, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. New England Journal of Medicine. 2019;380(9):822-832.
11. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecologic Oncology. 2006;103(3):1083-1090.